{
    "doi": "https://doi.org/10.1182/blood-2019-128568",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=4176",
    "start_url_page_num": 4176,
    "is_scraped": "1",
    "article_title": "Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry ",
    "article_date": "November 13, 2019",
    "session_type": "613.Acute Myeloid Leukemia: Clinical Studies",
    "topics": [
        "plerixafor",
        "propensity score method",
        "hematopoietic stem cell transplantation",
        "impedance threshold device",
        "karyotype determination procedure",
        "ms-like tyrosine kinase 3",
        "magnetic resonance cholangiography",
        "allogeneic hematopoietic stem cell transplant",
        "allopurinol",
        "complete remission"
    ],
    "author_names": [
        "Juan Miguel M. Bergua Burgues",
        "Isabel Cano-Ferri, Cano-Ferri",
        "David Mart\u00ednez-Cuadron, MD",
        "Blanca Boluda",
        "Pilar Mart\u00ednez-S\u00e1nchez",
        "Rebeca Rodr\u00edguez-Veiga, MD",
        "Jordi Esteve",
        "Susana Vives, MD",
        "Josefina Serrano",
        "Maria-Belen Vidriales, MD",
        "Olga Salamero, MD",
        "Carlos Carretero",
        "Ana Jimenez-Ubieto",
        "Ignacio Casas, MD",
        "Rocio Cardesa, MD",
        "Marina Diaz-Bey\u00e1, MD",
        "Salut Brunet, MD PhD",
        "Celina Benavente",
        "Jose Antonio P\u00e9rez-Sim\u00f3n",
        "Federico Moscardo, MD",
        "Eliana Aguiar",
        "Manuel Perez Encinas, MD",
        "Aurelio L\u00f3pez Mart\u00ednez, MD",
        "Carlos Rguez",
        "A. Cabello, MD",
        "Jorge Labrador",
        "Lissette Del Pilar Costilla, MD",
        "Claudia Sossa, MD",
        "Teresa Bernal Del Castillo, MD PhD",
        "Miguel A. Sanz",
        "Pau Montesinos, MD PhD"
    ],
    "author_affiliations": [
        [
            "Hematology, Hospital Universitario San Pedro de Alcantara. Caceres, Caceres, ESP "
        ],
        [
            "Hematology, Hospital La Fe Valenica, Valencia, Spain "
        ],
        [
            "Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain "
        ],
        [
            "Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain "
        ],
        [
            "Hematology, Hospital 12 de Octubre. Madrid, Madrid, Spain "
        ],
        [
            "Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain "
        ],
        [
            "Hospital Clinic of Barcelona, Barcelona, ESP ",
            "Hospital Clinic, Dept. of Hematology, IDIBAPS, Barcelona, Spain, Barcelona, Spain ",
            "IDIBAPS, University of Barcelona, Hematology Department, Hospital Cl\u00ednic, Barcelona, Spain ",
            "Hospital Cl\u00ednic, Barcelona, Spain "
        ],
        [
            "Clinical Hematology, ICO-Hospital Germans Trias i Pujol. Josep Carreras Research Institute. Universitat Aut\u00f2noma de Barcelona, Badalona, Spain "
        ],
        [
            "Clinical Hematology, Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba, Spain "
        ],
        [
            "Hematology Department, Hospital Cl\u00ednico Universitario Salamanca (CAUSA/IBSAL), Salamanca, Spain "
        ],
        [
            "Department of Hematology. Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron., Barcelona, Spain,, Barcelona, Spain "
        ],
        [
            "Hospital Universitari I Polit\u00e8Cnic La Fe, Valencia, ESP "
        ],
        [
            "Hospital 12 de Octubre. Madrid, Madrid, Spain "
        ],
        [
            "Hematology, Hospital San Pedro de Alcantara. C\u00e1ceres, Caceres, Spain "
        ],
        [
            "Hematology, Hospital San Pedro de Alcantara. C\u00e1ceres, C\u00e1ceres, Spain "
        ],
        [
            "Hematology department, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain "
        ],
        [
            "Hematology department, Hospital de la Santa Creu i Sant Pau, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain "
        ],
        [
            "Hospital Clinico San Carlos. Madrid, Madrid, Spain "
        ],
        [
            "Department of Hematology, Hospital Universitario Virgen del Rocio; Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla,Spain, Sevilla, Spain "
        ],
        [
            "Hematology, Hospital La Fe. Valencia, Valencia, Spain "
        ],
        [
            "Hospital Sao Joao. Oporto, Porto, Portugal "
        ],
        [
            "Hospital Cl\u00ednico Universitario de Santiago de Compostela, Santiago de Compostela, Spain "
        ],
        [
            "Clinical Hematology, Hospital Arnau de Vilanova, Valencia, Spain "
        ],
        [
            "Hospital Gran Canaria Dr Negr\u00edn, Las Palmas, ESP "
        ],
        [
            "Hematology, Hospital La Candelaria. Tenerife, Santa Cruz de Tenerife, Spain "
        ],
        [
            "Hematology, Hospital de Burgos, Burgos, Spain "
        ],
        [
            "Hematology, Hospital Miguel Servet. Zaragoza, Zaragoza, Spain "
        ],
        [
            "Hematology, Hospital FOSCAL. Bucaramanga, Bucaramanga, Colombia "
        ],
        [
            "Central de Asturias Universitary Hospital, Oviedo, Spain ",
            "Fundaci\u00f3n General de la Universidad de Salamanca, Oviedo, ESP ",
            "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Oviedo, Spain ",
            "Hospital Universitario Central Asturias, Oviedo, Spain "
        ],
        [
            "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Instituto Carlos III, Madrid, Spain ",
            "CIBERONC, Madrid, Spain ",
            "Department of Medicine, University of Valencia, Valencia, Spain ",
            "Servicio de Hematolog\u00eda. Hospital La Fe, Valencia, Spain, Valencia, ESP ",
            "Hematology Department, University and Polytechnic Hospital La Fe, Valencia, Spain "
        ],
        [
            "Hospital Universitari i Polit\u00e8cnic La Fe, Valencia & CIBERONC, Instituto Carlos III, Madrid, Spain"
        ]
    ],
    "first_author_latitude": "39.465023599999995",
    "first_author_longitude": "-6.3677506",
    "abstract_text": "BACKGROUND AND OBJECTIVES: Chemosensitization using plerixafor combined with FLAG-IDA (PLERIFLAG regimen) showed promising results (48% CR/CRi) in a phase 2 trial for primary refractory and early relapsed (duration of first CR <12 months) Adult AML patients. We aim to compare retrospectively results of the PLERIFLAG cohort versus historical cohorts of patients salvaged with FLAG-IDA (Fludarabine, Idarubicine, Cytarabine, G-CSF as priming agent), or FLAGO-IDA (Gemtuzumab plus FLAG-IDA) registered in the PETHEMA epidemiologic AML registry (NCT02006004). To match different cohorts, we used two risk-score classifications: EPI/HOVON (De Breems, JCO 2005) and SALFLAGE (Bergua, BJH 2016). The purpose is to analyse the complete remission (CR+CRi) rate, the rate of patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT). The disease-free survival (DFS) and overall survival (OS) were adjusted using established risk factors (time to relapse (TTR), karyotype, FLT3-ITD, previous stem cell transplant (SCT)) using propensity score analysis. Patients: Of the 540 patients in the data base we analysed 300 patients relapsed or resistant to induction therapy, which had all data available. 241 patients were treated with FLAG-IDA, 41 with FLAGO-Ida, and 42 with PLERIFLAG. Differences between treatment cohorts were tested using Fisher exact test. Treatment cohorts (PLERIFLAG vs FLAG-IDA vs FLAGO-IDA) were similar in Age (p=0.5), Sex (p=0.5), FLT3-ITD mutated (p=0.5), EPI/HOVON cytogenetics score (p=0.5) and previous myelodisplasia (p=0.2). The three cohorts differed in time to relapse (p=0.001), previous stem cell transplantation (0.001), HOVON score (p=0.03) and SALFLAGE score (0.001). RESULTS There were no differences in terms of CR+CRi between the three types of treatment adjusted by Hovon risk score (Pleriflag: 48%, FLAG-IDA: 50% or FLAGO-IDA: 58%; Chrochan Maentel-Haenszel test, p=0.466) or SALFLAGE score (Chrochan-Maentel-Haenszel test, p=0.23). More patients were allografted in the PLERIFLAG (61%) group even not achieving CR/Cri, as compared to FLAG-IDA (38%) or FLAGO-Ida (61% vs 38% vs. 18%, p=0.0001). To compare PLERIFLAG against the other two types of salvage treatment we performed a Propensity Score in a proportion 1:3. We adjust variables like age, previous allogeneic transplant, time to relapse (refractory, 12 months), karyotype using MRC, and FLT3-ITD status. Karyotype risk was considered by HOVON criteria (inv16, t(8;21) vs others), and SALFLAGE (inv 16, intermediate risk, and unfavourable risk by MRC risk plus t(8;21)). The propensity score analyses showed that Compared to FLAG-IDA, PLERIFLAG was associated to increased survival (median OS 10.56 months vs. 5.6, p=0.03), but not improved EFS (2.83 months vs 1.41 months, p=0.8). The benefit in OS but not in EFS could be explained in part by frequent use of Allo SCT in patients who had not achieve CR/CRi in the PLERIFLAG cohort. In conclusion, our historical control study show that PLERIFLAG regimen is an acceptable therapeutic option for first relapsed/refractory adult AML patients. Disclosures Esteve: Jazz Pharmaceuticals: Consultancy; Amgen: Consultancy; Pfizer: Consultancy; Novartis: Consultancy, Research Funding, Speakers Bureau; Celgene: Consultancy, Speakers Bureau; Daiichi Sankyo: Consultancy; Roche: Consultancy; Astellas: Consultancy, Speakers Bureau. Salamero: Novartis: Honoraria; Pfizer: Honoraria; Celgene: Honoraria; Daichii Sankyo: Honoraria. Perez Encinas: CELGENE: Consultancy; JANSSEN: Consultancy; GILEAD SCIENCES: Research Funding. Montesinos: Incyte: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Research support, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Other: Research support, Research Funding, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: Research support, Research Funding, Speakers Bureau; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Research support, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Other: Research support; Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Research support, Research Funding, Speakers Bureau; Teva: Membership on an entity's Board of Directors or advisory committees, Other: Research support, Research Funding, Speakers Bureau."
}